We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genomic Assay Predicts Biochemical Failure and Risk of Metastasis in Prostate Cancer Patients After Surgery and Radiation Therapy

By LabMedica International staff writers
Posted on 13 Aug 2014
An advanced genomic test has been used to predict the course of prostate cancer in patients following surgery and radiation treatment.

Investigators at Thomas Jefferson University (Philadelphia, PA, USA) used the commercially available GenomeDx Biosciences (San Diego, CA, USA) Decipher assay system to analyze the genomes from tumor samples from 139 patients who had received radiation therapy following prostate surgery.

Decipher is a genomic test carried out on a small tissue sample that was removed during surgery, which measures the expression levels of 22 RNA biomarkers involved in multiple biological pathways across the genome associated with aggressive prostate cancer. More...
The Decipher test uses the expression of these biomarkers to calculate the probability of clinical metastasis within five years of radical prostatectomy surgery and within three years of successive PSA rise (biochemical recurrence).

Results revealed that Decipher correctly predicted biochemical failure and risk of metastasis after prostate cancer postsurgical irradiation. It was suggested that patients with lower risk as defined by Decipher would benefit from delayed radiation treatment, as opposed to those with higher Decipher scores. However, this needs prospective validation in order to become generally accepted. Nonetheless, genomic-based models may be useful for improved decision-making for treatment of high-risk prostate cancer.

"We are moving away from treating everyone the same," said first author Dr. Robert Den, assistant professor of radiation oncology and cancer biology at Thomas Jefferson University. "Genomic tools are letting us gauge which cancers are more aggressive and should be treated earlier with radiation, and which ones are unlikely to benefit from additional therapy. Our analysis suggests that genomic analysis scores could be used, in concert with other diagnostic measures such as PSA testing, to help determine which patients would benefit from additional radiation therapy and more aggressive measures, and which are less likely to benefit."

The study was published in the July 8, 2014, online edition of the International Journal of Radiation Oncology*Biology*Physics.

Related Links:

Thomas Jefferson University
GenomeDx Biosciences



Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Serological Pipet Controller
PIPETBOY GENIUS
New
Francisella Tularensis Test
TULAREMIA VIRCLIA IgG+IgM MONOTEST
New
Myocardial Infarction Test
Finecare cTn I/NT-proBNP Rapid Quantitative Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The proprietary multiomic platform unlocks disease-associated biomarkers from a range of biological sources (Photo courtesy of Tagomics)

Highly Sensitive and Specific Test to Enable Early Detection of Colorectal Cancer

A highly sensitive and specific diagnostic test for the early detection and treatment of colorectal cancer could enable treatment at the earliest possible stages of disease development. Tagomics Ltd.... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Microbiology

view channel
Image: The LIAISON PLEX® Gram-Positive Blood Culture Assay runs on the on the LIAISON PLEX instrument (Photo courtesy of Diasorin)

Blood Culture Assay Enhances Diagnostic Stewardship Through Targeted Panel Selection

Each year, around 250,000 individuals in the US are diagnosed with bloodstream infections (BSIs). Sepsis caused by these infections carries a mortality rate ranging from 16% to 40%, and any delay in administering... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.